Airsculpt Technologies Inc
NASDAQ:AIRS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.35
8.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Airsculpt Technologies Inc
Airsculpt Technologies Inc
Cost of Revenue
Airsculpt Technologies Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Airsculpt Technologies Inc
NASDAQ:AIRS
|
Cost of Revenue
-$68.1m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DaVita Inc
NYSE:DVA
|
Cost of Revenue
-$8.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cost of Revenue
-$6.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cost of Revenue
-$316.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-11%
|
|
|
Cigna Corp
NYSE:CI
|
Cost of Revenue
-$206.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cost of Revenue
-$9.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
|
Airsculpt Technologies Inc
Glance View
AirSculpt Technologies, Inc. operates as a blank check company. The company is headquartered in Miami Beach, Florida and currently employs 240 full-time employees. The company went IPO on 2021-10-29. The firm's activities are conducted through the Professional Associations and its wholly owned subsidiaries, which owns and operates the non-clinical assets and provide management services. The company offers patients a range of customized body contouring procedures, including fat removal and fat transfer. The firm also offers fat transfer procedures that uses the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its fat transfer procedures include Power Brazilian Butt Lift (BBL), a Brazilian butt lift procedure; Up a Cup, a breast enhancement procedure, and the Hip Flip, an hourglass contouring procedure. The firm also leverages AirSculpt TV, which allows viewers into procedure rooms to watch its surgeons use AirSculpt body contouring procedure. The company operates in approximately 16 centers across 13 states.
See Also
What is Airsculpt Technologies Inc's Cost of Revenue?
Cost of Revenue
-68.1m
USD
Based on the financial report for Dec 31, 2023, Airsculpt Technologies Inc's Cost of Revenue amounts to -68.1m USD.
What is Airsculpt Technologies Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-49%
Over the last year, the Cost of Revenue growth was -17%. The average annual Cost of Revenue growth rates for Airsculpt Technologies Inc have been -49% over the past three years .
You don't have any saved screeners yet
